These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 32226768)
1. Hematopoietic stem cell transplantation in mucopolysaccharidosis type IIIA: A case description and comparison with a genotype-matched control group. Köhn AF; Grigull L; du Moulin M; Kabisch S; Ammer L; Rudolph C; Muschol NM Mol Genet Metab Rep; 2020 Jun; 23():100578. PubMed ID: 32226768 [TBL] [Abstract][Full Text] [Related]
2. Early Umbilical Cord Blood-Derived Stem Cell Transplantation Does Not Prevent Neurological Deterioration in Mucopolysaccharidosis Type III. Welling L; Marchal JP; van Hasselt P; van der Ploeg AT; Wijburg FA; Boelens JJ JIMD Rep; 2015; 18():63-8. PubMed ID: 25256447 [TBL] [Abstract][Full Text] [Related]
4. An observational, prospective, multicenter, natural history study of patients with mucopolysaccharidosis type IIIA. Wijburg FA; Aiach K; Chakrapani A; Eisengart JB; Giugliani R; Héron B; Muschol N; O'Neill C; Olivier S; Parker S Mol Genet Metab; 2022 Feb; 135(2):133-142. PubMed ID: 34991944 [TBL] [Abstract][Full Text] [Related]
5. The mutation p.Ser298Pro in the sulphamidase gene (SGSH) is associated with a slowly progressive clinical phenotype in mucopolysaccharidosis type IIIA (Sanfilippo A syndrome). Meyer A; Kossow K; Gal A; Steglich C; Mühlhausen C; Ullrich K; Braulke T; Muschol N Hum Mutat; 2008 May; 29(5):770. PubMed ID: 18407553 [TBL] [Abstract][Full Text] [Related]
6. An Engineered Douek AM; Amiri Khabooshan M; Henry J; Stamatis SA; Kreuder F; Ramm G; Änkö ML; Wlodkowic D; Kaslin J Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073041 [TBL] [Abstract][Full Text] [Related]
7. The Neurobehavioral Phenotype in Mucopolysaccharidosis Type IIIB: an Exploratory Study. Shapiro E; King K; Ahmed A; Rudser K; Rumsey R; Yund B; Delaney K; Nestrasil I; Whitley C; Potegal M Mol Genet Metab Rep; 2016 Mar; 6():41-47. PubMed ID: 26918231 [TBL] [Abstract][Full Text] [Related]
8. Early enzyme replacement therapy enables a successful hematopoietic stem cell transplantation in mucopolysaccharidosis type IH: Divergent clinical outcomes in two Japanese siblings. Yamazaki N; Kosuga M; Kida K; Takei G; Fukuhara Y; Matsumoto H; Senda M; Honda A; Ishiguro A; Koike T; Yabe H; Okuyama T Brain Dev; 2019 Jun; 41(6):546-550. PubMed ID: 30755342 [TBL] [Abstract][Full Text] [Related]
10. Quantifying medical manifestations in Hurler syndrome with the infant physical symptom score: associations with long-term physical and adaptive outcomes. Ahmed A; Rudser K; King KE; Eisengart JB; Orchard PJ; Shapiro E; Whitley CB Mol Genet Metab; 2022 May; 136(1):22-27. PubMed ID: 35304037 [TBL] [Abstract][Full Text] [Related]
11. Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: Diagnostic, clinical, and biological implications. Yogalingam G; Hopwood JJ Hum Mutat; 2001 Oct; 18(4):264-81. PubMed ID: 11668611 [TBL] [Abstract][Full Text] [Related]
12. Successful use of an eye gaze AAC communication board by a young adult with advanced Sanfilippo Syndrome (MPS IIIA): Case report. Brennan C; Matthews A; Tennant S Ther Adv Rare Dis; 2024; 5():26330040241275672. PubMed ID: 39228859 [TBL] [Abstract][Full Text] [Related]
13. [Postnatal and prenatal diagnosis of mucopolysaccharidosis type III (Sanfilippo syndrome)]. Zhang WM; Shi HP; Meng Y; Li BT; Qiu ZQ; Liu JT Zhonghua Er Ke Za Zhi; 2008 Jun; 46(6):407-10. PubMed ID: 19099774 [TBL] [Abstract][Full Text] [Related]
14. A prospective one-year natural history study of mucopolysaccharidosis types IIIA and IIIB: Implications for clinical trial design. Truxal KV; Fu H; McCarty DM; McNally KA; Kunkler KL; Zumberge NA; Martin L; Aylward SC; Alfano LN; Berry KM; Lowes LP; Corridore M; McKee C; McBride KL; Flanigan KM Mol Genet Metab; 2016 Nov; 119(3):239-248. PubMed ID: 27590925 [TBL] [Abstract][Full Text] [Related]
15. Systemic scAAV9.U1a.hSGSH Delivery Corrects Brain Biochemistry in Mucopolysaccharidosis Type IIIA at Early and Later Stages of Disease. Saville JT; Derrick-Roberts ALK; McIntyre C; Fuller M Hum Gene Ther; 2021 Apr; 32(7-8):420-430. PubMed ID: 33339477 [TBL] [Abstract][Full Text] [Related]
16. Bioinformatics classification of mutations in patients with Mucopolysaccharidosis IIIA. Tanwar H; Kumar DT; Doss CGP; Zayed H Metab Brain Dis; 2019 Dec; 34(6):1577-1594. PubMed ID: 31385193 [TBL] [Abstract][Full Text] [Related]
17. Longitudinal MRI brain volume changes over one year in children with mucopolysaccharidosis types IIIA and IIIB. Abreu NJ; Selvaraj B; Truxal KV; Moore-Clingenpeel M; Zumberge NA; McNally KA; McBride KL; Ho ML; Flanigan KM Mol Genet Metab; 2021 Jun; 133(2):193-200. PubMed ID: 33962822 [TBL] [Abstract][Full Text] [Related]
18. The natural history of neurocognition in MPS disorders: A review. Shapiro EG; Eisengart JB Mol Genet Metab; 2021 May; 133(1):8-34. PubMed ID: 33741271 [TBL] [Abstract][Full Text] [Related]
19. Functional correction of CNS lesions in an MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes. Fraldi A; Hemsley K; Crawley A; Lombardi A; Lau A; Sutherland L; Auricchio A; Ballabio A; Hopwood JJ Hum Mol Genet; 2007 Nov; 16(22):2693-702. PubMed ID: 17725987 [TBL] [Abstract][Full Text] [Related]